Roche To Acquire Spark Therapeutics For $4.3 Billion.

Reuters (2/25, Miller) reports Roche Holding AG will pay $4.3 billion, or $114.50 per share, to acquire gene therapy specialist Spark Therapeutics. Roche will acquire a “portfolio that includes a blindness treatment that has U.S. and European approval and...